Market Place
Sourcing Support
Pepgen Announces Regulatory Updates On FREEDOM2
04 Mar 2026 //
BUSSINESSWIRE
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results
04 Mar 2026 //
BUSSINESSWIRE
PepGen Names Joseph Vittiglio Chief Business And Legal Officer
08 Dec 2025 //
PHARMIWEB
PepGen Closes Public Offering, Underwriters Exercise Full Option
26 Sep 2025 //
BUSINESSWIRE
PepGen`s Q2 2025 Financial Results and Corporate Highlights
07 Aug 2025 //
BUSINESSWIRE
PepGen Appoints Kasra Kasraian as Chief Technology Officer
20 May 2025 //
BUSINESSWIRE
PepGen Reports Q1 2025 Financial Results and Corporate Highlights
08 May 2025 //
BUSINESSWIRE
FDA hits pause on another of PepGen`s muscular dystrophy trials
16 Dec 2024 //
FIERCE BIOTECH
PepGen Announces Executive Team Promotions
11 Jun 2024 //
BUSINESSWIRE
PepGen Reports Q1 2024 Results, Corporate Highlights
14 May 2024 //
GLOBENEWSWIRE
PepGen to Participate in Upcoming Investor Conferences
13 Mar 2024 //
GLOBENEWSWIRE
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results
06 Mar 2024 //
GLOBENEWSWIRE
PepGen Announces Clearance of CTA to Begin CONNECT2-EDO51
04 Mar 2024 //
GLOBENEWSWIRE
PepGen Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
PepGen Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
PepGen Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
PepGen Announces Upcoming Data at the 2023 American Academy of Neurology
17 Apr 2023 //
GLOBENEWSWIRE
PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference
13 Apr 2023 //
GLOBENEWSWIRE
PepGen 4Q & 2022 FYR and Recent Corporate Developments
23 Mar 2023 //
GLOBENEWSWIRE
PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Conference
22 Mar 2023 //
GLOBENEWSWIRE
PepGen to Participate in the Stifel 2023 CNS Days Conference
21 Mar 2023 //
GLOBENEWSWIRE
PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call
16 Mar 2023 //
GLOBENEWSWIRE
PepGen Announces Upcoming Data Presentations at the 2023 Annual Conference
13 Mar 2023 //
GLOBENEWSWIRE
PepGen to Participate in the SVB Securities Global Biopharma Conference
09 Feb 2023 //
GLOBENEWSWIRE
PepGen Inc. has seen a significant decrease in short interest.
30 Dec 2022 //
BESTSTOCKS
PepGen Announces IND-Enabling Preclinical Data Supporting of PGN-EDODM1
07 Dec 2022 //
GLOBENEWSWIRE
PepGen Announces Positive Preclinical Data PGN-EDO53, PGN-EDO45 and PGN-EDO44
14 Nov 2022 //
GLOBENEWSWIRE
PepGen Presents Data from its Duchenne Muscular Dystrophy Program
13 Oct 2022 //
GLOBENEWSWIRE
PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51
28 Sep 2022 //
GLOBENEWSWIRE
PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate DevP
12 Aug 2022 //
GLOBENEWSWIRE
PepGen Appoints Caroline Godfrey, Ph.D. to Company’s Scientific Advisory Board
22 Jul 2022 //
GLOBENEWSWIRE
PepGen, Inc. Joins Innovation and Collaboration Space
20 Jun 2022 //
UMASS
PepGen Reports Q1 2022 Financial Results and Corporate Developments
16 Jun 2022 //
GLOBENEWSWIRE
Newly public PepGen sees stock plunge 19%
23 May 2022 //
SEEKING ALPHA
PepGen Announces Pricing of Initial Public Offering
05 May 2022 //
GLOBENEWSWIRE
RA-backed PepGen sets terms for IPO; Sanofi commences dosing of Denali candidate
02 May 2022 //
ENDPTS
PepGen Continues to Build Leadership Team
30 Mar 2022 //
GLOBENEWSWIRE
PepGen says Approval by HC of CTA to Begin First in Human Trials of PGN-EDO51
15 Mar 2022 //
GLOBENEWSWIRE
PepGen To Present Research at Two Scientific Conferences in September
20 Sep 2021 //
GLOBENEWSWIRE
PepGen Announces New Additions to Leadership Team and Board of Directors
31 Aug 2021 //
GLOBENEWSWIRE
PepGen Announces Closing of $112.5M Crossover Financing
05 Aug 2021 //
GLOBENEWSWIRE
PepGen raises $113M to challenge Sarepta in DMD
05 Aug 2021 //
FIERCEBIOTECH
